Form 4: Capricor Therapeutics Director Awarded Stock Options

A Capricor Therapeutics director, Karimah Es Sabar, was granted stock options for board service, including both vesting and fully vested options.

Summary

• Karimah Es Sabar, a director at Capricor Therapeutics, was granted multiple stock options on January 2, 2025.
• These options include 11,940 shares that vest monthly starting February 1, 2025, and concluding December 31, 2025.
• An additional 2,520 shares were granted and are fully vested immediately as of January 2, 2025.
• A further 5,750 shares were granted and are fully vested immediately as of January 2, 2025.
• All options have an exercise price of $14.96 and expire on January 2, 2035.
• The vesting options are subject to a repurchase option by the issuer if the director's service terminates before vesting.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of awarding stock options to a director, which is generally viewed positively as it aligns interests. There are no negative implications, but it's not a major positive catalyst either.

Positives

• The granting of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule for some options encourages continued service by the director.
• The immediate vesting of some options provides immediate incentive.

Risks

• The vesting options are subject to a repurchase option if the director's service terminates before vesting, which could lead to a loss of potential gains if service is terminated.
• The value of the options is dependent on the future performance of the company's stock.

Future Outlook

The director's future financial gains are tied to the company's stock performance.

Industry Context

Stock option grants are a common practice for compensating board members and aligning their interests with shareholders in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in the biotech industry, similar to companies like Amgen and Gilead Sciences.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms for incentivizing long-term commitment.
• The specific terms of the options, such as the repurchase option, are also common in the industry to protect the company's interests.

Stakeholder Impact

• Shareholders may view the stock option grants positively as they align the director's interests with the company's performance.
• The director is incentivized to contribute to the company's success to increase the value of their options.

Key Dates

Keywords

stock options, director, Capricor Therapeutics, vesting, equity, board service, insider trading